IL-3-zetakine 联合 CD33 共刺激受体作为双 CAR 策略以实现更安全、选择性地靶向 AML
IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML.
急性髓系白血病(AML)对成人和儿童患者而言仍是尚未满足的临床需求。
47.2分
★★★☆☆
FRONTIER PAPERS
IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML.
急性髓系白血病(AML)对成人和儿童患者而言仍是尚未满足的临床需求。
CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm.
尽管在基础研究和临床治疗层面不断取得进展,急性髓系白血病 (AML) 对成人和儿童患者而言仍是未被满足的临床需求。
Biological therapy in elderly patients with acute myeloid leukemia.
该治疗手段组合将成为多模式、个体化联合方案的基础,在精准医学理念下,将使老年 AML 患者极大获益。
共 3 条
MEMBER ACCOUNT
登录成功会直接打开下一页。